• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞封装作为一种潜在的非饮食疗法用于治疗母体苯丙酮尿症。

Cell encapsulation as a potential nondietary therapy for maternal phenylketonuria.

作者信息

Santillan Donna A, Santillan Mark K, Hunter Stephen K

机构信息

Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.

出版信息

Am J Obstet Gynecol. 2009 Sep;201(3):289.e1-6. doi: 10.1016/j.ajog.2009.05.035. Epub 2009 Jul 24.

DOI:10.1016/j.ajog.2009.05.035
PMID:19631922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8928171/
Abstract

OBJECTIVE

The objective of this work was to determine whether cells overexpressing phenylalanine (Phe) hydroxylase (PAH) can significantly reduce Phe in vitro for potential use as a therapy for preventing maternal phenylketonuria.

STUDY DESIGN

Human 293T and WRL68 cell lines were transiently and stably transfected to overexpress PAH. Cells were encapsulated within microspheres of sodium alginate. Timed measurements of Phe in media were performed using tandem mass spectrometry.

RESULTS

Both nonencapsulated and encapsulated transiently transfected cells overexpressing PAH significantly reduced the Phe concentration in media by approximately 50% in comparison to mock-transfected cells. Cell line clones stably expressing PAH significantly decreased the Phe concentration in the media by up to 85% compared with media alone.

CONCLUSION

Both unencapsulated and encapsulated cells overexpressing PAH significantly reduce Phe in vitro. Studies using phenylketonuria model mice will be important in determining the ability of our therapy to prevent the teratogenic effects of elevated maternal Phe in maternal phenylketonuria.

摘要

目的

本研究旨在确定过表达苯丙氨酸(Phe)羟化酶(PAH)的细胞是否能在体外显著降低苯丙氨酸水平,从而有可能作为预防母体苯丙酮尿症的一种治疗方法。

研究设计

对人293T和WRL68细胞系进行瞬时和稳定转染,使其过表达PAH。将细胞封装在海藻酸钠微球中。使用串联质谱法对培养基中的苯丙氨酸进行定时测量。

结果

与mock转染细胞相比,过表达PAH的未封装和封装的瞬时转染细胞均使培养基中的苯丙氨酸浓度显著降低了约50%。与单独的培养基相比,稳定表达PAH的细胞系克隆使培养基中的苯丙氨酸浓度显著降低了高达85%。

结论

过表达PAH的未封装和封装细胞均能在体外显著降低苯丙氨酸水平。使用苯丙酮尿症模型小鼠进行的研究对于确定我们的治疗方法预防母体苯丙酮尿症中母体苯丙氨酸升高的致畸作用的能力至关重要。

相似文献

1
Cell encapsulation as a potential nondietary therapy for maternal phenylketonuria.细胞封装作为一种潜在的非饮食疗法用于治疗母体苯丙酮尿症。
Am J Obstet Gynecol. 2009 Sep;201(3):289.e1-6. doi: 10.1016/j.ajog.2009.05.035. Epub 2009 Jul 24.
2
Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).来自野生型或杂合子供体的肝细胞在实现对鼠苯丙酮尿症(PKU)的成功治疗性肝再灌注中效果相同。
Mol Genet Metab. 2011 Nov;104(3):235-40. doi: 10.1016/j.ymgme.2011.07.027. Epub 2011 Aug 4.
3
Blood phenylalanine reduction reverses gene expression changes observed in a mouse model of phenylketonuria.血液苯丙氨酸降低可逆转苯丙酮尿症小鼠模型中观察到的基因表达变化。
Sci Rep. 2021 Nov 24;11(1):22886. doi: 10.1038/s41598-021-02267-2.
4
Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.通过重组腺相关病毒8假型载体介导的基因转移,在小鼠模型中对苯丙酮尿症(PKU)进行与给药途径和性别无关的长期治疗性矫正
Gene Ther. 2006 Apr;13(7):587-93. doi: 10.1038/sj.gt.3302684.
5
Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome.苯丙氨酸羟化酶基因对母体苯丙酮尿症结局的影响。
Pediatrics. 2003 Dec;112(6 Pt 2):1530-3.
6
Erythrocytes encapsulated with phenylalanine hydroxylase exhibit improved pharmacokinetics and lowered plasma phenylalanine levels in normal mice.包被有苯丙氨酸羟化酶的红细胞在正常小鼠中表现出改善的药代动力学和降低的血浆苯丙氨酸水平。
Mol Genet Metab. 2013 Aug;109(4):339-44. doi: 10.1016/j.ymgme.2013.05.011. Epub 2013 Jul 16.
7
Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.通过腺相关病毒介导在小鼠肌肉中表达完整的苯丙氨酸羟化系统来纠正小鼠苯丙酮尿症。
Mol Ther. 2008 Apr;16(4):673-81. doi: 10.1038/mt.2008.17. Epub 2008 Mar 11.
8
Quantification of phenylalanine hydroxylase activity by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry.同位素稀释液相色谱-电喷雾串联质谱法定量测定苯丙氨酸羟化酶活性。
Mol Genet Metab. 2012 Apr;105(4):559-65. doi: 10.1016/j.ymgme.2011.12.025. Epub 2012 Jan 12.
9
Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing.利用校正编辑技术快速、明确地治疗变异型人源化小鼠的苯丙酮尿症。
Nat Commun. 2023 Jun 10;14(1):3451. doi: 10.1038/s41467-023-39246-2.
10
Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.口服聚乙二醇化苯丙氨酸氨裂解酶治疗苯丙酮尿症的小鼠评价。
Mol Genet Metab. 2011 Nov;104(3):249-54. doi: 10.1016/j.ymgme.2011.06.016. Epub 2011 Jun 29.

本文引用的文献

1
[Correction of a diabetes mellitus type 1 on primate with encapsulated islet of pig pancreatic transplant].[猪胰腺移植包封胰岛对灵长类动物1型糖尿病的纠正作用]
Bull Mem Acad R Med Belg. 2007;162(10-12):439-49; discussion 449-50.
2
Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria.苯丙酮尿症中四氢生物蝶呤(BH4)反应性的评估。
J Pediatr. 2007 Jun;150(6):627-30. doi: 10.1016/j.jpeds.2007.02.017.
3
The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study.大剂量中性氨基酸补充剂对苯丙酮尿症的影响:一项磁共振波谱和神经心理学研究。
Mol Genet Metab. 2007 May;91(1):48-54. doi: 10.1016/j.ymgme.2007.02.002. Epub 2007 Mar 23.
4
Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.大中性氨基酸治疗苯丙酮尿症的双盲安慰剂对照试验:对血苯丙氨酸的影响
J Inherit Metab Dis. 2007 Apr;30(2):153-8. doi: 10.1007/s10545-007-0556-4. Epub 2007 Feb 27.
5
Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.通过重组腺相关病毒8假型载体介导的基因转移,在小鼠模型中对苯丙酮尿症(PKU)进行与给药途径和性别无关的长期治疗性矫正
Gene Ther. 2006 Apr;13(7):587-93. doi: 10.1038/sj.gt.3302684.
6
Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?苯丙氨酸解氨酶,苯丙酮尿症的酶替代疗法,我们现在进展如何?
Mol Genet Metab. 2005 Dec;86 Suppl 1:S22-6. doi: 10.1016/j.ymgme.2005.06.016. Epub 2005 Sep 13.
7
Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria.用于苯丙酮尿症酶替代治疗的基于结构的化学修饰策略
Mol Genet Metab. 2005 Sep-Oct;86(1-2):134-40. doi: 10.1016/j.ymgme.2005.05.012. Epub 2005 Jul 11.
8
Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria.用于治疗经典型苯丙酮尿症的重组红酵母苯丙氨酸解氨酶聚乙二醇化形式的研发。
Mol Ther. 2005 Jun;11(6):986-9. doi: 10.1016/j.ymthe.2005.02.013.
9
Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer.腺相关病毒载体介导的基因转移在苯丙酮尿症小鼠模型中的长期酶学和表型纠正
Pediatr Res. 2004 Aug;56(2):278-84. doi: 10.1203/01.PDR.0000132837.29067.0E. Epub 2004 Jun 4.
10
Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice.通过腺相关病毒介导的基因转移对高苯丙氨酸血症进行长期纠正可使苯丙酮尿症小鼠的行为恢复。
Gene Ther. 2004 Jul;11(13):1081-6. doi: 10.1038/sj.gt.3302262.